Abstract
Syndecan-4 (SDC4), expressed on dendritic cells (DCs) and activated T cells, plays a crucial role in DC motility and has been shown as a potential target for activated T-cell-driven diseases. In the present study, we investigate the role of SDC4 in the development of T-helper 2 cell-mediated allergic asthma. Using SDC4-deficient mice or an anti-SDC4 antibody we show that the absence or blocking of SDC4 signalling in ovalbumin-sensitized mice results in a reduced asthma phenotype compared with control animals. Most importantly, even established asthma is significantly decreased using the anti-SDC4 antibody. The disturbed SDC4 signalling leads to an impaired motility and directional migration of antigen-presenting DCs and therefore, to a modified sensitization leading to diminished airway inflammation. Our results demonstrate that SDC4 plays an important role in asthma induction and indicate SDC4 as possible target for therapeutic intervention in this disease.
Introduction
Allergic asthma is a chronic inflammatory disease driven by an overactive T-helper 2 (Th2) immune response to otherwise harmless allergens. The "spark" for this inflammatory fire is the dendritic cell (DC). DCs act as scouts: they capture allergens in the lungs and must migrate to local lymph nodes to "present" these allergens to T cells, which then orchestrate the full-blown allergic attack. While we know DCs are essential, the molecular machinery they use to navigate from the lung to the lymph node is not fully mapped. This study investigates Syndecan-4 (SDC4), a cell-surface protein known to be involved in cell adhesion and migration, as a potential key "GPS" or "engine" that DCs use during asthma development.
Methods
The study utilized a combination of genetic and pharmacological approaches in murine models of asthma. Researchers compared wild-type (WT) mice to SDC4-deficient ($SDC4^{-/-}$) mice using an ovalbumin (OVA) sensitization model. Additionally, they employed a polyclonal anti-SDC4 antibody to block SDC4 signaling in both preventative and therapeutic protocols. To elucidate the mechanism, the team performed adoptive transfer experiments, tracking fluorescently labeled DCs from the trachea to the mediastinal lymph nodes using flow cytometry. Molecular interactions were further explored via co-immunoprecipitation (Co-IP) to examine SDC4 binding to the chemokine CCL21.
Key Results
The absence or blocking of SDC4 resulted in a dramatic reduction of the asthmatic phenotype. $SDC4^{-/-}$ mice exhibited significantly lower levels of airway hyperresponsiveness (AHR) and a marked decrease in eosinophil recruitment to the lungs. Furthermore, OVA-specific IgE levels—the primary antibody responsible for allergic triggers—were significantly reduced in the absence of SDC4 signaling.
Tracking experiments confirmed a migration deficit: SDC4-deficient DCs showed a significant decrease in their ability to reach the mediastinal lymph nodes. Crucially, in the therapeutic model, anti-SDC4 treatment reduced the degree of lung inflammation by more than 50% even after asthma was established, highlighting its potential as a clinical target.
Key Insights: Localized vs. Systemic Effects
A significant finding of this study is that SDC4 primarily controls the local recruitment and activation of the immune response rather than inducing systemic immunosuppression. While Th2 cytokine production (such as IL-5 and IL-13) was slashed in the local mediastinal lymph nodes, it remained largely unchanged—or even slightly elevated—in the spleen.
This suggests that SDC4 acts as a chemokine tether, interacting directly with CCL21 to help DCs "sense" the chemical signals leading to the lymph nodes. Without SDC4, DCs lose their directional "compass," failing to reach the sites necessary to activate the T cells that drive asthma symptoms.
Discussion and Future Directions
While SDC4 is a promising target, its ubiquitous expression on various cell types, including B cells and activated T cells, presents challenges for systemic therapy. SDC4 is also involved in physiological processes like wound healing. Future research should focus on localized delivery methods or identifying ways to target SDC4 specifically on dendritic cells within the lung to minimize off-target effects. Additionally, validating these findings in human DC migration assays is a necessary step toward clinical translation.
Summary updated